Regeneron Pharmaceuticals
REGN
1,312 hedge funds and large institutions have $89.3B invested in Regeneron Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 148 funds opening new positions, 484 increasing their positions, 451 reducing their positions, and 94 closing their positions.
57% more first-time investments, than exits
New positions opened: 148 | Existing positions closed: 94
11% more capital invested
Capital invested by funds: $80.8B → $89.3B (+$8.57B)
3% more funds holding
Funds holding: 1,273 → 1,312 (+39)
7% more repeat investments, than reductions
Existing positions increased: 484 | Existing positions reduced: 451
0.29% more ownership
Funds ownership: 85.81% → 86.09% (+0.29%)
0% more funds holding in top 10
Funds holding in top 10: 25 → 25 (0)
40% less call options, than puts
Call options by funds: $971M | Put options by funds: $1.63B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.15B |
| 2 |
JP Morgan Chase
New York
|
+$476M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$453M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$226M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$210M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$457M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$452M |
| 3 |
Holocene Advisors
New York
|
-$265M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$196M |
| 5 |
D.E. Shaw & Co
New York
|
-$127M |
REGN Hedge Fund Activity: Q1 2024 in Review
1,312 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2024, worth a combined $89.3B — up 11% from $80.8B a quarter earlier.
Buyers outnumbered sellers: 148 funds opened new REGN positions and 94 closed out — a net gain of 54 holders — while 484 added to existing stakes and 451 trimmed.
The largest buyer was Franklin Resources, adding an estimated $1.15B. The largest seller was Neuberger Berman Group, cutting an estimated $457M.
- 1,312 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2024, up from 1,273 in Q4 2023.
- Funds reported $89.3B of Regeneron Pharmaceuticals stock for Q1 2024, up 11% quarter-over-quarter.
- 148 funds opened new Regeneron Pharmaceuticals positions in Q1 2024 and 94 closed out, a net change of +54 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2024 was Franklin Resources, an estimated $1.15B added.
- The largest Regeneron Pharmaceuticals seller in Q1 2024 was Neuberger Berman Group, an estimated $457M sold.
Based on aggregated 13F filings for Q1 2024.